查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1511811

美国血红蛋白病市场规模、份额和趋势分析报告：按类型、诊断、治疗、地区和细分市场预测，2024-2030 年

U.S. Hemoglobinopathies Market Size, Share & Trends Analysis Report By Type (Thalassemia, Sickle Cell Disease), By Diagnosis (Thalassemia, Sickle Cell Disease), By Therapy, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 80 Pages | 商品交期: 2-10个工作天内

价格

美国血红蛋白病市场的成长与趋势：

Grand View Research, Inc.的最新报告显示，到2030年，美国血红素病市场规模预计将达到68.5亿美元，2024年至2030年复合年增长率为12.5%。

镰状细胞疾病和地中海贫血等血红素病患疾病率的上升是一个关键的市场驱动因素。基因检测和产前筛检等诊断技术的进步改善了血红蛋白疾病的早期检测。此外，基因疗法和CRISPR-Cas9等基因编辑技术等新治疗方案的研究正在取得进展，未来有望获得更有效的治疗方法。

政府不断采取措施提高对血红蛋白血症的认识并改善受影响个人获得护理的机会，这在推动市场方面发挥关键作用。研究和开发资金也在加速这一领域的创新。

製药公司、研究机构和医疗保健提供者之间的合作将加速新治疗方法的开发并改善患者护理。利用各公司优势的合作关係可以加速药物开发并改善治疗结果。

美国血红素病市场报告亮点

  • 到 2023 年，镰状细胞疾病在该类型细分市场中占据主导地位，占 60.1%，预计在预测期内将以最快的复合年增长率增长。这一成长的推动因素是生物製药公司和非营利组织为改善镰状细胞疾病 (SCD) 治疗的可及性而采取的越来越多的倡议。
  • 到2023年，镰状细胞疾病诊断领域将占据最大市场。包括次世代定序和分子诊断等基因检测方法的进步正在推动这一领域的成长。
  • 到 2023 年，镰状细胞疾病治疗领域将占据最大市场。市场成长是由越来越多的创新治疗方法获得核准所推动的，例如基因疗法和旨在纠正遗传异常的标靶治疗。
  • 2022年4月，基因组医学公司Sangamo Therapeutics宣布将其SAR445136镰状细胞疾病计画从赛诺菲转移至Sangamo。这一转变代表了镰状细胞疾病基因编辑治疗开发的重要一步。

目录

第一章调查方法和范围

第 2 章执行摘要

第 3 章美国血红素病市场变数、趋势、范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场推动要素分析
    • 市场限制因素分析
  • 美国血红素病市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章美国血红蛋白病市场：类型估计和趋势分析

  • 2023年及2030年市场占有率
  • 细分仪表板
  • 按类型分類的市场前景
  • 2018-2030年市场规模及预测及趋势分析

第五章美国血红素疾病市场：诊断估计与趋势分析

  • 2023年及2030年市场占有率
  • 细分仪表板
  • 诊断市场前景
  • 2018-2030年市场规模及预测及趋势分析

第六章美国血红素病市场：治疗估计与趋势分析

  • 2023年及2030年市场占有率
  • 细分仪表板
  • 不同疗法的市场前景
  • 2018-2030年市场规模及预测及趋势分析

第七章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 供应商情况
  • 公司简介
    • Sangamo Therapeutics, Inc.
    • Global Blood Therapeutics, Inc.
    • bluebird bio, Inc.
    • Emmaus Life Sciences Inc.
    • Pfizer, Inc.
    • Novartis AG
    • Prolong Pharmaceuticals, LLC
    • Bioverativ Inc.
    • Celgene Corp.
Product Code: GVR-4-68040-295-9

U.S. Hemoglobinopathies Market Growth & Trends:

The U.S. hemoglobinopathies market size is anticipated to reach USD 6.85 billion by 2030, growing at a CAGR of 12.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising prevalence of hemoglobinopathies, such as sickle cell disease and thalassemia, is a significant market driver. Advances in diagnostic techniques, such as genetic testing and prenatal screening, have improved the early detection of hemoglobinopathies. In addition, ongoing research into novel treatment options, including gene therapy and gene editing technologies like CRISPR-Cas9, holds promise for more effective therapies in the future.

The growing government initiatives to raise awareness about hemoglobinopathies and improved access to care for affected individuals play a crucial role in driving the market. Funding support for research and development efforts also accelerates innovation in this field.

Collaboration between pharmaceutical companies, research institutions, and healthcare providers fosters the development of new therapies and enhances patient care. Partnerships that leverage companies' strengths can accelerate drug development and improve treatment outcomes.

U.S. Hemoglobinopathies Market Report Highlights:

  • Sickle cell disease type dominated the type segment with 60.1% share in 2023 and is expected to grow at fastest CAGR over the forecast period. The growth is attributed to the increasing Initiatives of Biopharmaceutical Companies and Nonprofit Organizations Driving Improved Access to Sickle Cell Disease (SCD) Treatment.
  • The sickle cell disease diagnosis segment held the largest market in 2023. Advancements including genetic testing methods such as next-generation sequencing and molecular diagnostics are propelling the segment growth.
  • The sickle cell disease therapy segment held the largest market in 2023. The growing approval of innovative therapies, such as gene therapies and targeted treatments, designed to modify genetic abnormalities are propelling market growth.
  • In April 2022, Sangamo Therapeutics, a genomic medicines company, announced the transition of its SAR445136 sickle cell disease program from Sanofi to Sangamo. This transition marks a significant step in the development of a gene-edited therapy for sickle cell disease.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Diagnosis
    • 1.2.3. Therapy
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Volume price analysis (Model 2)
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type outlook
    • 2.2.2. Diagnosis outlook
    • 2.2.3. Therapy outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Hemoglobinopathies Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. U.S. Hemoglobinopathies Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's Five Forces
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. U.S. Hemoglobinopathies Market: Type Estimates & Trend Analysis

  • 4.1. Type Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. U.S. Hemoglobinopathies Market by Type Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
    • 4.4.1. Thalassemia
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Sickle cell disease
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Other Hb variants
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Hemoglobinopathies Market: Diagnosis Estimates & Trend Analysis

  • 5.1. Diagnosis Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. U.S. Hemoglobinopathies Market by Diagnosis Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
    • 5.4.1. Thalassemia
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.2. Alpha
      • 5.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.2.2. Blood test
      • 5.4.1.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.2.3. Genetic test
      • 5.4.1.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.2.4. Prenatal genetic test
      • 5.4.1.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.2.5. Pre-implantation genetic test
      • 5.4.1.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.2.6. Electrophoresis
      • 5.4.1.2.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.2.7. Others
      • 5.4.1.2.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.3. Beta
      • 5.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.3.2. Blood test
      • 5.4.1.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.3.3. Genetic test
      • 5.4.1.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.3.4. Prenatal genetic test
      • 5.4.1.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.3.5. Pre-implantation genetic test
      • 5.4.1.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.3.6. Electrophoresis
      • 5.4.1.3.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.3.7. Others
      • 5.4.1.3.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Sickle cell disease
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.2. Blood test
      • 5.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.3. Genetic test
      • 5.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.4. Prenatal genetic test
      • 5.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.5. Electrophoresis
      • 5.4.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.6. Others
      • 5.4.2.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Hb variants
      • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.3.2. Blood test
      • 5.4.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.3.3. Genetic test
      • 5.4.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.3.4. Prenatal genetic test
      • 5.4.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.3.5. Electrophoresis
      • 5.4.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.3.6. Others
      • 5.4.3.7. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Hemoglobinopathies Market: Therapy Estimates & Trend Analysis

  • 6.1. Therapy Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. U.S. Hemoglobinopathies Market by Therapy Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
    • 6.4.1. Thalassemia
      • 6.4.1.1. Market estimates and forecasts 2018 to 2030, (USD million)
      • 6.4.1.2. Alpha
      • 6.4.1.2.1. Market estimates and forecasts 2018 to 2030, (USD million)
      • 6.4.1.2.2. Blood transfusion
      • 6.4.1.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.2.2.2. Iron chelation therapy
      • 6.4.1.2.2.3. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.2.3. Bone marrow transplant
      • 6.4.1.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.2.4. Others
      • 6.4.1.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.3. Beta
      • 6.4.1.3.1. Market estimates and forecasts 2018 to 2030, (USD million)
      • 6.4.1.3.2. Blood transfusion
      • 6.4.1.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.3.2.2. Iron chelation therapy
      • 6.4.1.3.2.3. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.3.3. Bone marrow transplant
      • 6.4.1.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.3.4. Others
      • 6.4.1.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Sickle Cell Disease
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.2.2. Blood transfusion
      • 6.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.2.3. Hydroxyurea
      • 6.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.2.4. Bone marrow transplant
      • 6.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.2.5. Others
      • 6.4.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. (Hb) Variants
      • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.3.2. Blood transfusion
      • 6.4.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.3.3. Hydroxyurea
      • 6.4.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.3.4. Bone marrow transplant
      • 6.4.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.3.5. Others
      • 6.4.3.6. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company heat map analysis, 2023
  • 7.4. Company Profiles
    • 7.4.1. Sangamo Therapeutics, Inc.
      • 7.4.1.1. Company overview
      • 7.4.1.2. Financial performance
      • 7.4.1.3. Product benchmarking
      • 7.4.1.4. Strategic initiatives
    • 7.4.2. Global Blood Therapeutics, Inc.
      • 7.4.2.1. Company overview
      • 7.4.2.2. Financial performance
      • 7.4.2.3. Product benchmarking
      • 7.4.2.4. Strategic initiatives
    • 7.4.3. bluebird bio, Inc.
      • 7.4.3.1. Company overview
      • 7.4.3.2. Financial performance
      • 7.4.3.3. Product benchmarking
      • 7.4.3.4. Strategic initiatives
    • 7.4.4. Emmaus Life Sciences Inc.
      • 7.4.4.1. Company overview
      • 7.4.4.2. Financial performance
      • 7.4.4.3. Product benchmarking
      • 7.4.4.4. Strategic initiatives
    • 7.4.5. Pfizer, Inc.
      • 7.4.5.1. Company overview
      • 7.4.5.2. Financial performance
      • 7.4.5.3. Product benchmarking
      • 7.4.5.4. Strategic initiatives
    • 7.4.6. Novartis AG
      • 7.4.6.1. Company overview
      • 7.4.6.2. Financial performance
      • 7.4.6.3. Product benchmarking
      • 7.4.6.4. Strategic initiatives
    • 7.4.7. Prolong Pharmaceuticals, LLC
      • 7.4.7.1. Company overview
      • 7.4.7.2. Financial performance
      • 7.4.7.3. Product benchmarking
      • 7.4.7.4. Strategic initiatives
    • 7.4.8. Bioverativ Inc.
      • 7.4.8.1. Company overview
      • 7.4.8.2. Financial performance
      • 7.4.8.3. Product benchmarking
      • 7.4.8.4. Strategic initiatives
    • 7.4.9. Celgene Corp.
      • 7.4.9.1. Company overview
      • 7.4.9.2. Financial performance
      • 7.4.9.3. Product benchmarking
      • 7.4.9.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 U.S. hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 3 U.S. hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 4 U.S. hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 5 U.S. thalassemia market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 6 U.S. hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 7 U.S. alpha thalassemia market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 8 U.S. beta thalassemia market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 9 U.S. thalassemia market, by therapy, 2018 - 2030 (USD Million)
  • Table 10 U.S. alpha thalassemia market, by therapy, 2018 - 2030 (USD Million)
  • Table 11 U.S. beta thalassemia market, by therapy, 2018 - 2030 (USD Million)
  • Table 12 U.S. sickle cell disease market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 13 U.S. sickle cell disease market, by therapy, 2018 - 2030 (USD Million)
  • Table 14 U.S. Hb Variants market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 15 U.S. hemoglobinopathies market, by region, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 U.S. hemoglobinopathies market: market outlook
  • Fig. 9 U.S. hemoglobinopathies competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 U.S. hemoglobinopathies market driver impact
  • Fig. 15 U.S. hemoglobinopathies market restraint impact
  • Fig. 16 U.S. hemoglobinopathies market strategic initiatives analysis
  • Fig. 17 U.S. hemoglobinopathies market: Type movement analysis
  • Fig. 18 U.S. hemoglobinopathies market: Type outlook and key takeaways
  • Fig. 19 Thalassemia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Sickle cell diseases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Other Hb variants estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 U.S. hemoglobinopathies Market: Diagnosis movement Analysis
  • Fig. 23 U.S. hemoglobinopathies market: Diagnosis outlook and key takeaways
  • Fig. 24 Thalassemia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Alpha market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Blood test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Prenatal genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Pre-implantation genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Electrophoresis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Other market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Beta market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Blood test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Prenatal genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Pre-implantation genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Electrophoresis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Other market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Sickle cell disease market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Blood test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Prenatal genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Electrophoresis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 (Hb) variants market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Blood test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Prenatal genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Electrophoresis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 U.S. hemoglobinopathies Market: Therapy movement Analysis
  • Fig. 52 U.S. hemoglobinopathies market: Therapy outlook and key takeaways
  • Fig. 53 Thalassemia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Alpha market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Blood transfusion market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Iron chelation therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Bone marrow transplant test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Beta market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Blood transfusion market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Iron chelation therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Bone marrow transplant test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Sickle cell disease market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Blood transfusion market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Hydroxyurea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Bone marrow transplant test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 (Hb) variants market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Blood transfusion market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 Hydroxyurea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Bone marrow transplant test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 U.S. hemoglobinopathies market: regional movement analysis
  • Fig. 75 U.S. hemoglobinopathies market: regional outlook and key takeaways
  • Fig. 76 West market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Midwest market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Northeast market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Southwest market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 Southeast market estimates and forecasts, 2018 - 2030 (USD Million)